Altimmune announced positive Phase 2 RECLAIM trial results for its next-gen GLP-1/glucagon dual agonist pemvidutide in alcohol use disorder, showing a statistically significant reduction in heavy drinking days per week versus placebo Pemvidutide 2.4 mg reduced heavy drinking days by 4.20 versus 2.75 in placebo, a 1.45-day placebo-adjusted difference (p=0.0014), and met key FDA-recognized secondary endpoints including two-level reduction in WHO risk drinking levels and zero heavy drinking days The drug was generally well tolerated, with predominantly gastrointestinal side effects and a 10% discontinuation rate due to adverse events, and demonstrated a 9.1% placebo-adjusted weight loss over six months, supporting its dual utility for AUD and obesity Sources: Press Release Press Release of Altimmune, Inc. dated March 5, 2026 - SEC.gov Lennart Pedersen's Post We’re proud to share that Altimmune has completed early enrollment in the RECLAIM Phase 2 trial evaluating our inv...
- Get link
- X
- Other Apps